参考文献
[1]Cancer Genome Atlas Research,N.Comprehensive molecular characterization of gastric adenocarcinoma[J].Nature,2014,513(7517):202-209.
[2]Tang,W.Epstein-barr virus infected gastric adenocarcinoma expresses latent and lytic viral transcripts and has a distinct human gene expression profile[J].Infect Agent Cancer,2012,7(1):21.
[3]Khan,G.,M.J.Hashim.Global burden of deaths from Epstein-Barr virus attributable malignancies 1990-2010[J].Infect Agent Cancer,2014.9(1):p.38.
[4]Iizasa,H.Epstein-Barr Virus(EBV)-associated gastric carcinoma[J].Viruses,2012,4(12):3420-3439.
[5]Camargo,M.C.Improved survival of gastric cancer with tumour Epstein-Barr virus positivity:an international pooled analysis[J].Gut,2014,63(2):236-243.
[6]Hoadley,K.A.Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin[J].Cell,2014,158(4):929-944.
[7]Sun,J.PD-L1 expression analysis in gastric carcinoma tissue and blocking of tumor-associated PD-L1 signaling by two functional monoclonal antibodies[J].Tissue Antigens,2007,69(1):19-27.
[8]McDermott,D.F.,M.B.Atkins.PD-1 as a potential target in cancer therapy[J].Cancer Med,2013,2(5):662-673.
[9]Kakiuchi,M.Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma[J].Nat Genet,2014,46(6):583-587.
[10]Ayed-Guerfali,D.B.Expression of APC,beta-catenin and E-cadherin in Tunisian patients with gastric adenocarcinoma:clinical significance[J].Tumour Biol,2014,35(3):1775-1783.
[11]Terashima,M.Impact of expression of human epidermal growth factor receptors EGFR and ERBB-2 on survival in stage Ⅱ/Ⅲ gastric cancer[J].Clin Cancer Res,2012,18(21):5992-6000.
[12]Roskoski,R.Jr.The ERBB/HER family of protein-tyrosine kinases and cancer[J].Pharmacol Res,2014,79:p.34-74.
[13]Chan,J.Al.A multicenter phase Ⅱ trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma[J].Ann Oncol,2011,22(6):p.1367-1373.
[14]Trarbach,T.Phase I study of matuzumab in combination with 5-fluorouracil,leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas[J].Invest New Drugs,2013,31(3):642-652.
[15]Sunakawa Y,Lenz HJ.Molecular classification of gastric adenocarcinoma：translating new insights from the cancer genome atlas research network[J].Curr Treat Options Oncol,2015,16(4):17.
[16]Lin SJ,Gagnon-Bartsch JA,Tan IB,et al.Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas[J].Gut,2015,64(11):1721-1731.
[17]Satoh,T.Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations:TyTAN-a randomized,phase Ⅲ study[J].J Clin Oncol,2014,32(19):2039-2049.
[18]Van Cutsem,E.Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer:a biomarker evaluation from the AVAGAST randomized phase Ⅲtrial[J].J Clin Oncol,2012,30(17):2119-2127.
[19]Fuchs,C.S.Ramucirumab monotherapy for previously treated advanced gastric or gastrooesophageal junction adenocarcinoma (REGARD):an international,randomised,multicentre,placebo-controlled,phase 3 trial[J].Lancet,2014,383(9911):31-39.
[20]Li,J.Apatinib for chemotherapy-refractory advanced metastatic gastric cancer:results from a randomized,placebo-controlled,parallel-arm,phase Ⅱ trial[J].J Clin Oncol,2013,31(26):3219-3225.(https://www.daowen.com)
[21]Sun,W.Phase Ⅱ study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma:ECOG 5203[J].J Clin Oncol,2010,28(18):2947-2951.
[22]Sun,D.F.Inhibition of mTOR signalling potentiates the effects of trichostatin A in human gastric cancer cell lines by promoting histone acetylation[J].Cell Biol Int,2014,38(1):50-63.
[23]Gao J,Huang W,Mu S,et al.The pathway regulating RhoA activity to predict the survival of gastric cancers[J].J Clin Oncol,2018,36(4_suppl):49.
[24]Deng X,Xiao Q,Liu F,et al.A gene expression-based risk model reveals prognosis of gastric cancer[J].Peer J,2018,6:e4204.
[25]Zhao,J.,X.Zhang,Y.Xin.Up-regulated expression of Ezrin and c-Met proteins are related to the metastasis and prognosis of gastric carcinomas[J].Histol Histopathol,2011,26(9):1111-1120.
[26]Hack,S.P.,J.M.Bruey,et al.HGF/MET-directed therapeutics in gastroesophageal cancer:a review of clinical and biomarker development[J].Oncotarget,2014,5(10):2866-2880.
[27]Iveson,T.Rilotumumab in combination with epirubicin,cisplatin,and capecitabine as firstline treatment for gastric or oesophagogastric junction adenocarcinoma:an open-label,dose de-escalation phase 1b study and a double-blind,randomised phase 2 study[J].Lancet Oncol,2014,15(9):1007-1018.
[28]Strickler,J.H.Phase I Dose-Escalation and Expansion Study of Telisotuzumab (ABT-700),an Anti-c-Met Antibody,in Patients with Advanced Solid Tumors[J].Mol Cancer Ther,2020,19(5):1210-1217.
[29]Hong,D.S.Phase I Study of AMG 337,a Highly Selective Small-molecule MET Inhibitor,in Patients with Advanced Solid Tumors[J].Clin Cancer Res,2019,25(8):2403-2413.
[30]Garnock-Jones,K.P.Ripasudil:first global approval[J].Drugs,2014,74(18):2211-2215.
[31]Tanaka,T.Expression level of sonic hedgehog correlated with the speed of gastric mucosa regeneration in artificial gastric ulcers[J].J Gastroenterol Hepatol,2014,29(4):736-741.
[32]Yoon,C.CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance[J].Clin Cancer Res,2014,20(15):3974-3988.
[33]Sobanko,J.F.,J.Okman,et al.Vismodegib:a hedgehog pathway inhibitor for locally advanced and metastatic basal cell carcinomas[J].J Drugs Dermatol,2013,12(10 Suppl):154-155.
[34]Gajjar,A.Phase I study of vismodegib in children with recurrent or refractory medulloblastoma:a pediatric brain tumor consortium study[J].Clin Cancer Res,2013,19(22):6305-6312.
[35]Katona BW,Rustgi AK.Gastric cancer genomics:advances and future directions[J].Cell Mol Gastroenterol Hepatol,2017,3(2):211-217.
[36]Lenz,H.J.,M.Kahn.Safely targeting cancer stem cells via selective catenin coactivator antagonism[J].Cancer Sci,2014,105(9):1087-1092.
[37]Li,K.,Z.Dan,Y.Q.Nie.Gastric cancer stem cells in gastric carcinogenesis,progression,prevention and treatment[J].World J Gastroenterol,2014,20(18):5420-5426.
[38]Du,X.Role of NOTCH signaling pathway in gastric cancer:a meta-analysis of the literature[J].World J Gastroenterol,2014,20(27):9191-9199.
[39]Huggett,M.T.Phase Ⅰ/Ⅱ study of verteporfin photodynamic therapy in locally advanced pancreatic cancer[J].Br J Cancer,2014,110(7):1698-1704.
[40]Waddell,T.Epirubicin,oxaliplatin,and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3):a randomised,openlabel phase 3 trial[J].Lancet Oncol,2013,14(6):481-489.